Role and mechanism of semaphorins in liver diseases

Manwula MUBARESI; Xuan DING; Yidan LUO; Qingshuai LIANG; Xu ZHOU; Yuwu LIU

doi:10.12449/JCH260632

Volume 42 Issue 6

Jun. 2026

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2026 > 42(6): 1454-1461

PDF( 898 KB)

Role and mechanism of semaphorins in liver diseases

DOI: 10.12449/JCH260632

Manwula MUBARESI^{1, 2},
Xuan DING^{1, 2},
Yidan LUO^{1, 2},
Qingshuai LIANG^{1, 2},
Xu ZHOU^{1, 3},
Yuwu LIU^{1, 4
,
,
,}

1.
Department of Pathology，School of Basic Medical Sciences，Xinjiang Medical University，Urumqi 830017，China
2.
The First Clinical Medical College of Xinjiang Medical University，Urumqi 830054，China
3.
The Sixth Clinical Medical College of Xinjiang Medical University，Urumqi 830054，China
4.
Xinjiang Key Laboratory of Molecular Biology for Endemic Diseases，Urumqi 830017，China

Research funding:

Xinjiang Medical University Undergraduate Innovation Training Program Project (S202410760081)

More Information

Corresponding author: LIU Yuwu， xjlyw-007@126.com （ORCID： 0000-0002-6329-120X）
Received Date: 2025-09-26
Accepted Date: 2025-11-05
Published Date: 2026-06-25

Abstract

Abstract

The liver is a vital metabolic organ sustaining human life activities， and its dysfunction is closely associated with various liver diseases. In recent years， an increasing number of studies have shown that semaphorins （SEMA） play a significant role in pathological processes such as immune inflammatory response， tumor progression， and fibrosis in liver diseases by interacting with their receptors plexins and neuropilins. This article reviews the expression， functions， and molecular mechanisms of different SEMA in viral hepatitis， hepatocellular carcinoma， liver fibrosis， nonalcoholic fatty liver disease， and hepatic ischemia-reperfusion injury， and it also explores the potential application value of SEMA in the diagnosis and treatment of liver diseases， in order to provide new ideas for precise diagnosis and targeted treatment of liver diseases.
- Semaphorins,
- Liver Disease,
- Plexin,
- Neuropilin

FullText(HTML)

References(47)

References

[1]	XU BN, ZHANG X, XIE WF. Role of hepatocyte nuclear factor 4α in liver diseases and its regulatory mechanism[J]. Chin J Dig, 2023, 43( 7): 491- 494. DOI: 10.3760/cma.j.cn311367-20230217-00073. 徐搏男, 张新, 谢渭芬. 肝细胞核因子4α在肝脏疾病中的作用及调控机制[J]. 中华消化杂志, 2023, 43( 7): 491- 494. DOI: 10.3760/cma.j.cn311367-20230217-00073.
[2]	DEVARBHAVI H, ASRANI SK, ARAB JP, et al. Global burden of liver disease: 2023 update[J]. J Hepatol, 2023, 79( 2): 516- 537. DOI: 10.1016/j.jhep.2023.03.017.
[3]	MA SY, PU C. miR-129-2-3p binds SEMA4C to regulate HCC development and inhibit the EMT[J]. Mutat Res, 2024, 829: 111872. DOI: 10.1016/j.mrfmmm.2024.111872.
[4]	GONG L, PAN GQ. Advances in axon guidance molecule SEMA5A[J]. Chongqing Med, 2020, 49( 15): 2566- 2571. DOI: 10.3969/j.issn.1671-8348.2020.15.034. 龚琳, 潘国庆. 神经导向分子SEMA5A的研究进展[J]. 重庆医学, 2020, 49( 15): 2566- 2571. DOI: 10.3969/j.issn.1671-8348.2020.15.034.
[5]	JIANG YX, LIU XY, GUO ZH, et al. Research progress on relationship between semaphorins family and asthma[J]. Int J Immunol, 2022, 45( 6): 651- 655. DOI: 10.3760/cma.j.issn.1673-4394.2022.06.016. 蒋云秀, 刘欣怡, 郭子涵, 等. 信号素家族与哮喘的研究进展[J]. 国际免疫学杂志, 2022, 45( 6): 651- 655. DOI: 10.3760/cma.j.issn.1673-4394.2022.06.016.
[6]	LU YJ, ZHANG SL, XU Q, et al. Advances in effect of Semaphorin family and their receptors on tumor angiogenesis[J]. Acad J Chin PLA Med Sch, 2015, 36( 10): 1056- 1060. DOI: 10.3969/j.issn.2095-5227.2015.10.025. 鲁艳杰, 张淑玲, 许倩, 等. Semaphorin家族及其受体对肿瘤血管生成影响的研究进展[J]. 解放军医学院学报, 2015, 36( 10): 1056- 1060. DOI: 10.3969/j.issn.2095-5227.2015.10.025.
[7]	WAGNER W, OCHMAN B, WAGNER W. Semaphorin 6 family-an important yet overlooked group of signaling proteins involved in cancerogenesis[J]. Cancers, 2023, 15( 23): 5536. DOI: 10.3390/cancers15235536.
[8]	LI J, LIANG X, JIANG J, et al. PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF[J]. Gut, 2022, 71( 1): 163- 175. DOI: 10.1136/gutjnl-2020-323395.
[9]	YANG H, CAI Q, XIN JJ, et al. SEMA6B induces macrophage-mediated inflammation and hepatocyte apoptosis in hepatitis B virus-related acute-on-chronic liver failure[J]. Theranostics, 2024, 14( 13): 5200- 5218. DOI: 10.7150/thno.97007.
[10]	PAPIC N, ZIDOVEC LEPEJ S, GORENEC L, et al. The association of semaphorins 3C, 5A and 6D with liver fibrosis stage in chronic hepatitis C[J]. PLoS One, 2018, 13( 12): e0209481. DOI: 10.1371/journal.pone.0209481.
[11]	WEN X, HE YJ, YUAN QQ, et al. Expression of Sema4D in peripheral blood T cells and serum of patients with hepatitis B cirrhosis and its clinical significance[J]. J Clin Hepatol, 2023, 39( 4): 810- 817. DOI: 10.3969/j.issn.1001-5256.2023.04.011. 温雪, 何昱静, 袁倩倩, 等. Sema4D在乙型肝炎肝硬化患者外周血T淋巴细胞和血清中的表达及意义[J]. 临床肝胆病杂志, 2023, 39( 4): 810- 817. DOI: 10.3969/j.issn.1001-5256.2023.04.011.
[12]	YANG SQ, WANG L, PAN W, et al. MMP2/MMP9-mediated CD100 shedding is crucial for inducing intrahepatic anti-HBV CD8 T cell responses and HBV clearance[J]. J Hepatol, 2019, 71( 4): 685- 698. DOI: 10.1016/j.jhep.2019.05.013.
[13]	MA SY, ZHANG BC, LI XR, et al. miR-3612 regulates the malignant biological behaviors of hepatocellular carcinoma cells via targeting SEMA4C[J]. Chin J Cancer Biother, 2024, 31( 3): 231- 239. DOI: 10.3872/j.issn.1007-385x.2024.03.004. 马思源, 张博超, 李贤锐, 等. miR-3612靶向SEMA4C调控肝细胞癌细胞的恶性生物学行为[J]. 中国肿瘤生物治疗杂志, 2024, 31( 3): 231- 239. DOI: 10.3872/j.issn.1007-385x.2024.03.004.
[14]	PENG H, YANG M, FENG K, et al. Semaphorin 3C(Sema3C) reshapes stromal microenvironment to promote hepatocellular carcinoma progression[J]. Signal Transduct Target Ther, 2024, 9( 1): 169. DOI: 10.1038/s41392-024-01887-0.
[15]	LIU HJ, YE H, LI XZ. Effect of microrna-138 on epithelial-Mesenchymal transition and invasion of breast cancer cells by targeting semaphorin 4C[J]. Bioengineered, 2021, 12( 2): 10117- 10125. DOI: 10.1080/21655979.2021.2000733.
[16]	HUANG YD, BAI QY, YU HB, et al. Circ-POLA2-mediated miR-138-5p/SEMA4C axis affects colon cancer cell activities[J]. Acta Biochim Pol, 2023, 70( 3): 517- 523. DOI: 10.18388/abp.2020_6457.
[17]	LU J, LIN YX, LI FY, et al. miR-205 suppresses tumor growth, invasion, and epithelial-mesenchymal transition by targeting SEMA4C in hepatocellular carcinoma[J]. FASEB J, 2018. DOI: 10.1096/fj.201800113R.[ Epub ahead of print]
[18]	YU ZJ, DU YH, LI HY, et al. miR-642 serves as a tumor suppressor in hepatocellular carcinoma by regulating SEMA4C and p38 MAPK signaling pathway[J]. Oncol Lett, 2020, 20( 4): 74. DOI: 10.3892/ol.2020.11935.
[19]	BORRELLI C, ROBERTS M, ELETTO D, et al. In vivo interaction screening reveals liver-derived constraints to metastasis[J]. Nature, 2024, 632( 8024): 411- 418. DOI: 10.1038/s41586-024-07715-3.
[20]	NAGY GN, ZHAO XF, KARLSSON R, et al. Structure and function of Semaphorin-5A glycosaminoglycan interactions[J]. Nat Commun, 2024, 15( 1): 2723. DOI: 10.1038/s41467-024-46725-7.
[21]	ZUO QZ, YANG YK, LYU YJ, et al. Plexin-B3 expression stimulates MET signaling, breast cancer stem cell specification, and lung metastasis[J]. Cell Rep, 2023, 42( 3): 112164. DOI: 10.1016/j.celrep.2023.112164.
[22]	WANG Y, ZHANG S, ZHANG JG, et al. Effect of SEMA5A on cell proliferation and apoptosis of hepatocellular carcinoma and possible mechanism[J]. Chin J Cancer Prev Treat, 2023, 30( 7): 397- 405. DOI: 10.16073/j.cnki.cjcpt.2023.07.04. 王燕, 张曙, 章建国, 等. SEMA5A对肝细胞癌增殖及凋亡的影响及可能机制[J]. 中华肿瘤防治杂志, 2023, 30( 7): 397- 405. DOI: 10.16073/j.cnki.cjcpt.2023.07.04.
[23]	JIANG CX, ZHANG XX, ZHANG S, et al. Expression and clinical significance of SEMA5A and Ki-67 in hepatocellular carcinoma[J]. Chin J Clin Exp Pathol, 2023, 39( 2): 151- 156. DOI: 10.13315/j.cnki.cjcep.2023.02.005. 姜晨霞, 章小霞, 张曙, 等. 肝细胞癌中Semaphorin5A及Ki-67的表达及其临床意义[J]. 临床与实验病理学杂志, 2023, 39( 2): 151- 156. DOI: 10.13315/j.cnki.cjcep.2023.02.005.
[24]	WANG K, HE M, FAN X, et al. SEMA5A-PLXNB3 axis promotes PDAC liver metastasis outgrowth through enhancing the Warburg effect[J]. J Immunol Res, 2023, 2023: 3274467. DOI: 10.1155/2023/3274467.
[25]	MA Y, ZHANG ZY, CAO XL, et al. Semaphorin 6A phase separation sustains a histone lactylation-dependent lactate buildup in pathological angiogenesis[J]. Proc Natl Acad Sci USA, 2025, 122( 16): e2423677122. DOI: 10.1073/pnas.2423677122.
[26]	JI J, XU YX, XIE MR, et al. VHL-HIF-2α axis-induced SEMA6A upregulation stabilized β-catenin to drive clear cell renal cell carcinoma progression[J]. Cell Death Dis, 2023, 14( 2): 83. DOI: 10.1038/s41419-023-05588-4.
[27]	SONG ZB, YU Y, ZHANG GP, et al. Genomic instability of mutation-derived gene prognostic signatures for hepatocellular carcinoma[J]. Front Cell Dev Biol, 2021, 9: 728574. DOI: 10.3389/fcell.2021.728574.
[28]	YU SM, ZHANG M, LI SL, et al. Long noncoding RNA semaphorin 6A-antisense RNA 1 reduces hepatocellular carcinoma by promoting semaphorin 6A mRNA degradation[J]. World J Gastroenterol, 2025, 31( 13): 102527. DOI: 10.3748/wjg.v31.i13.102527.
[29]	LORIA R, LAQUINTANA V, SCALERA S, et al. SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma[J]. J Exp Clin Cancer Res, 2022, 41( 1): 148. DOI: 10.1186/s13046-022-02354-w.
[30]	LORIA R, BON G, PEROTTI V, et al. Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells[J]. Oncotarget, 2015, 6( 5): 2779- 2793. DOI: 10.18632/oncotarget.2995.
[31]	SEGARRA M, OHNUKI H, MARIC D, et al. Semaphorin 6A regulates angiogenesis by modulating VEGF signaling[J]. Blood, 2012, 120( 19): 4104- 4115. DOI: 10.1182/blood-2012-02-410076.
[32]	LIAO ZH, XIE ZY. Research progress in molecular mechanism of hepatic fibrosis and related therapeutic targets[J]. J Jilin Univ Med Ed, 2024, 50( 5): 1450- 1456. DOI: 10.13481/j.1671-587X.20240532. 廖昭辉, 谢正元. 肝纤维化发病的分子机制及其相关治疗靶点的研究进展[J]. 吉林大学学报(医学版), 2024, 50( 5): 1450- 1456. DOI: 10.13481/j.1671-587X.20240532.
[33]	ABIDAN BHTYE, GUO JS. Metabolic adaptation of activated hepatic stellate cells during hepatic fibrogenesis[J]. Chin J Cell Biol, 2021, 43( 10): 2054- 2060. DOI: 10.11844/cjcb.2021.10.0014. 阿比丹·拜合提亚尔, 郭津生. 肝纤维化发生时活化肝星状细胞的代谢改变[J]. 中国细胞生物学学报, 2021, 43( 10): 2054- 2060. DOI: 10.11844/cjcb.2021.10.0014.
[34]	de ANGELIS RIGOTTI F, WIEDMANN L, HUBERT MO, et al. Semaphorin 3C exacerbates liver fibrosis[J]. Hepatology, 2023, 78( 4): 1092- 1105. DOI: 10.1097/HEP.0000000000000407.
[35]	CAO S, YAQOOB U, DAS A, et al. Neuropilin-1 promotes cirrhosis of the rodent and human liver by enhancing PDGF/TGF-beta signaling in hepatic stellate cells[J]. J Clin Invest, 2010, 120( 7): 2379- 2394. DOI: 10.1172/JCI41203.
[36]	CAO XY, TANG YH, YUAN M. Research progress of semaphorin 7A in immune inflammation and nervous system diseases[J]. Curr Immunol, 2022, 42( 4): 340- 343. 曹湘玉, 汤永红, 袁梅. 信号素7A在免疫炎症及神经系统疾病中的研究进展[J]. 现代免疫学, 2022, 42( 4): 340- 343.
[37]	de MINICIS S, RYCHLICKI C, AGOSTINELLI L, et al. Semaphorin 7A contributes to TGF-β-mediated liver fibrogenesis[J]. Am J Pathol, 2013, 183( 3): 820- 830. DOI: 10.1016/j.ajpath.2013.05.030.
[38]	WANG LF, LIAO Y, YANG RB, et al. Sja-miR-71a in Schistosome egg-derived extracellular vesicles suppresses liver fibrosis caused by schistosomiasis via targeting semaphorin 4D[J]. J Extracell Vesicles, 2020, 9( 1): 1785738. DOI: 10.1080/20013078.2020.1785738.
[39]	ŠAMADAN L, PAPIĆ N, MIJIĆ M, et al. Do semaphorins play a role in development of fibrosis in patients with nonalcoholic fatty liver disease?[J]. Biomedicines, 2022, 10( 12): 3014. DOI: 10.3390/biomedicines10123014.
[40]	PLEIN A, FANTIN A, RUHRBERG C. Neuropilin regulation of angiogenesis, arteriogenesis, and vascular permeability[J]. Microcirculation, 2014, 21( 4): 315- 323. DOI: 10.1111/micc.12124.
[41]	ZHANG F, ZARKADA G, HAN J, et al. Lacteal junction zippering protects against diet-induced obesity[J]. Science, 2018, 361( 6402): 599- 603. DOI: 10.1126/science.aap9331.
[42]	EBERHARD D, BALKENHOL S, KÖSTER A, et al. Semaphorin-3A regulates liver sinusoidal endothelial cell porosity and promotes hepatic steatosis[J]. Nat Cardiovasc Res, 2024, 3( 6): 734- 753. DOI: 10.1038/s44161-024-00487-z.
[43]	PAN Q, LUO G, QU JQ, et al. A homozygous R148W mutation in Semaphorin 7A causes progressive familial intrahepatic cholestasis[J]. EMBO Mol Med, 2021, 13( 11): e14563. DOI: 10.15252/emmm.202114563.
[44]	ZHAO N, ZHANG XX, DING JJ, et al. SEMA7AR148W mutation promotes lipid accumulation and NAFLD progression via increased localization on the hepatocyte surface[J]. JCI Insight, 2022, 7( 15): e154113. DOI: 10.1172/jci.insight.154113.
[45]	LI SJ, XU TF, YUAN GD, et al. Advances in basic and clinical research on hepatic ischemia-reperfusion injury[J]. Chin J Exp Surg, 2023, 40( 10): 1925- 1930. DOI: 10.3760/cma.j.cn421213-20230207-01048. 李双江, 徐挺锋, 袁观斗, 等. 肝脏缺血再灌注损伤的临床与基础研究进展[J]. 中华实验外科杂志, 2023, 40( 10): 1925- 1930. DOI: 10.3760/cma.j.cn421213-20230207-01048.
[46]	WORZFELD T, OFFERMANNS S. Semaphorins and plexins as therapeutic targets[J]. Nat Rev Drug Discov, 2014, 13( 8): 603- 621. DOI: 10.1038/nrd4337.
[47]	KÖNIG K, GRANJA T, ECKLE VS, et al. Inhibition of plexin C1 protects against hepatic ischemia-reperfusion injury[J]. Crit Care Med, 2016, 44( 8): e625-32. DOI: 10.1097/CCM.0000000000001609.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (43) PDF downloads(18)

Role and mechanism of semaphorins in liver diseases

DOI: 10.12449/JCH260632

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Role and mechanism of semaphorins in liver diseases

DOI: 10.12449/JCH260632

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content